JNJ 64304500Alternative Names: JNJ 64304500 AAA; JNJ-64304500
Latest Information Update: 23 Feb 2017
$50 / €47 *
At a glance
- Originator Janssen
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
Most Recent Events
- 21 Dec 2016 Janssen Pharmaceutical plans a phase I trial in Healthy volunteers in Japan (SC) (NCT03002025).
- 01 Dec 2016 Phase-I clinical trials in Crohn's disease (In volunteers) in Japan (SC) (NCT03002025)
- 11 Nov 2016 Phase-II clinical trials in Crohn's disease in Hungary (SC) (EudraCT2016-000634-21)